After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary of the enormous […]
Shire accepts $64B takeover bid from Takeda
Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. Read the whole story on our sister site, […]
Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement
Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]
Allergan, Takeda spar for Shire
Allergan (NYSE: AGN) today confirmed that it’s in the running to acquire Shire (NSDQ:SHPGY), which rejected a $63 billion offer from Takeda Pharmaceutical (TYO:4502). Dublin-based Allergan, which is in the process of slashing 1,400 jobs from its payroll and exploring “strategic actions,” said there’s no guarantee it will make an offer for Shire. Get the full story at our sister […]
Fine-tuning formulation with Fluid Imaging Technologies’ FlowCam
After seven people died in 2013 from serious allergic reactions to Omontys, an injectable anemia drug marketed by Takeda Pharmaceutical (TYO:4502) and Affymax, the companies recalled the product and regulators launched an investigation to find out the cause of such an unexpected rate of anaphylaxis. Omontys was made and cleared in a single-use vial and a multi-use […]
Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain
Denali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases. The deal includes Denali’s preclinical Alzheimer’s projects, among other undisclosed candidates, which make use of the company’s antibody transport vehicles, or ATVs, to penetrate the blood-brain barrier. Get the full story at our sister […]
Takeda, Portal Instruments ink $100m deal to combine biologics and needle-free drug delivery
Takeda Pharmaceutical (TYO:4502) and Portal Instruments said today that the pair inked a collaboration to develop and commercialize Portal’s needle-free drug delivery device with Takeda’s biologic medicines. The first development program is slated to combine Takeda’s monoclonal antibody for adults with moderately- to severely-active ulcerative colitis or Crohn’s disease with Portal’s technology. The investigational therapy is currently administered […]
Why Takeda thinks partnerships can revive innovation in pharma
Takeda Pharmaceutical (TYO:4502) has been on a partnership spree lately, inking at least 65 collaborations and deal in the last 18 months. Fueling those agreements is a fundamental belief that to reinvigorate the pharmaceutical industry, access to innovative science is crucial, according to Daniel Curran, SVP & head of the Japan-based company’s Center for External Innovation. Get […]
Takeda partners to develop novel oncology therapies
Takeda Pharmaceutical (TYO:4502), through its subsidiary Millennium Pharmaceuticals, and Molecular Templates said today that the companies inked a deal to collaborate on an oncology drug discovery program. The deal is slated to combine Molecular Templates’ engineered toxin bodies platform with therapeutic targets provided by Takeda. Get the full story at our sister site, Drug Delivery Business […]
Takeda, BioSurfaces collab on GI drug-delivery devices
Takeda Pharmaceutical (TYO:4502) and BioSurfaces said today that the two companies inked a deal to develop novel medical devices intended to treat patients with gastrointestinal diseases. The deal brings together Takeda’s experience in the gastroenterology space and BioSurfaces’ method of developing nanomaterials from FDA-approved polymers for medical implants and drug-delivery devices. Financial terms of the deal were not […]
Aptar Pharma’s nasal spray compliance device wins EMA nod
Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company. The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals […]
MassDevice Network
@MassDevice
LinkedIn
YouTube